ALK and non-small cell lung carcinoma: This scenario may be analogous to observations in NSCLC patients harbouring ALK rearrangements, in whom the next-generation ALK inhibitor ceritinib can induce responses in patients who developed resistance to the less potent inhibitor crizotinib45, 46.